Skip to content

Randomized, open, parallel controlled clinical study of anisodine hydrobromide in acute lacunar infarction

Randomized, open, parallel controlled clinical study of anisodine hydrobromide in acute lacunar infarction

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035411
Enrollment
Unknown
Registered
2020-08-10
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lacunar infarction

Interventions

experimental group:Conventional treatment + anisodine hydrobromide
control group:Conventional treatment

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and above, sex is not limited; 2. Lacunar infarction was diagnosed by CT or magnetic resonance imaging (MRI), with or without white matter lesions; 3. Patients with acute lumen infarction were conscious, but with mild cognitive impairment; 4. NIHSS score was 3-15; 5. Understand and sign informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Severe disturbance of consciousness (NIHSS score IA >= 2); 2. Lacunar infarction caused by large artery infarction; 3. Brain imaging examination confirmed that there were diseases leading to similar symptoms, such as brain tumor, encephalitis, brain abscess, etc., or hemorrhagic cerebral infarction, epidural hematoma, etc; 4. Patients with serious heart disease, serious arrhythmia and heart failure; 5. Patients with severe abnormal liver and kidney function (ALT > 2uln, renal function laboratory index CR > 1.5uln); 6. Patients with a history of mental illness or dementia; 7. Significant drug or alcohol abuse; 8. Allergic constitution, and allergy to two or more drugs or foods; or known to be allergic to ingredients of the drug; 9. Pregnant, planned or lactating women; 10. Participated in other clinical trials in the past 3 months; 11. Patients who were not suitable for the study were determined by the researchers.

Design outcomes

Primary

MeasureTime frame
Improvement of neural function and cognitive function;

Secondary

MeasureTime frame
Changes of ADL and Fazekas scores;Incidence of combined vascular events (including stroke, myocardial infarction, vascular death and angina pectoris) at 90 days after onset;Recurrence of lacunar infarction on day 90 and 180;Mortality rate;

Countries

China

Contacts

Public ContactZhang Xiangjian

The Second Hospital of Hebei Medical University

zhang6xj@aliyun.com+86 15803210578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026